Compare BRUN & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRUN | AAPG |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2026 | 2024 |
| Metric | BRUN | AAPG |
|---|---|---|
| Price | $16.62 | $16.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $48.40 |
| AVG Volume (30 Days) | ★ 2.4M | 5.6K |
| Earning Date | N/A | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $290.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.56 | $16.23 |
| 52 Week High | $40.46 | $40.70 |
| Indicator | BRUN | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 42.67 |
| Support Level | $16.34 | $16.56 |
| Resistance Level | $20.91 | $18.45 |
| Average True Range (ATR) | 1.68 | 0.37 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 14.81 | 17.60 |
Boost Run Inc is an NVIDIA Cloud Provider. Its platform provides GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. Enterprises rely on Boost Run to power their main demanding AI workloads with the performance, security, and reliability their operations require. The group maintains SOC 2 Type II, HIPAA, ISO 27001, and ISO 27701 certifications at the operator level, and partners with data center facilities that uphold equivalent security and compliance standards.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.